Research programme: ghrelin receptor antagonists - AEterna Zentaris

Drug Profile

Research programme: ghrelin receptor antagonists - AEterna Zentaris

Alternative Names: 1,2,4-Triazole based ghrelin receptor ligands as anti-obesity agents - AEterna Zentaris; AEZS-123; JMV 2760; JMV 2959; JMV 3018; JMV 3534

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zentaris
  • Developer AEterna Zentaris GmbH; AEterna Zentaris Inc; University of Milan; University of Montpellier I; University of Montpellier II; University of Montreal
  • Class Small molecules; Triazoles
  • Mechanism of Action Ghrelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alcoholism; Obesity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in France
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top